Compare Stocks: INKT, FTFT, KROS, and ABOS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.85 -9.8%	$2.62	$1.21 ▼ $3.60	$228.52M	0.37	365,782 shs	369,217 shs
FTFT Future FinTech Group	$2.09 +59.5%	$4.33	$1.22 ▼ $248.32	$12.28M	1.8	988,930 shs	76.99 million shs
INKT MiNK Therapeutics	$11.90 +3.9%	$11.17	$8.48 ▼ $16.98	$58.43M	0.49	7,837 shs	16,848 shs
KROS Keros Therapeutics	$11.31 +1.3%	$10.84	$9.69 ▼ $22.55	$221.47M	1.01	167,664 shs	188,506 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-9.81%	-8.06%	+17.28%	+20.25%	+97.92%
FTFT Future FinTech Group	+59.54%	+19.43%	-35.52%	-85.87%	-98.75%
INKT MiNK Therapeutics	+3.93%	+5.03%	+8.68%	-3.57%	-22.53%
KROS Keros Therapeutics	+1.25%	+0.71%	+5.80%	+12.54%	-28.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.85 -9.8%	$2.62	$1.21 ▼ $3.60	$228.52M	0.37	365,782 shs	369,217 shs
FTFT Future FinTech Group	$2.09 +59.5%	$4.33	$1.22 ▼ $248.32	$12.28M	1.8	988,930 shs	76.99 million shs
INKT MiNK Therapeutics	$11.90 +3.9%	$11.17	$8.48 ▼ $16.98	$58.43M	0.49	7,837 shs	16,848 shs
KROS Keros Therapeutics	$11.31 +1.3%	$10.84	$9.69 ▼ $22.55	$221.47M	1.01	167,664 shs	188,506 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-9.81%	-8.06%	+17.28%	+20.25%	+97.92%
FTFT Future FinTech Group	+59.54%	+19.43%	-35.52%	-85.87%	-98.75%
INKT MiNK Therapeutics	+3.93%	+5.03%	+8.68%	-3.57%	-22.53%
KROS Keros Therapeutics	+1.25%	+0.71%	+5.80%	+12.54%	-28.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.33	Hold	$8.00	180.70% Upside
FTFT Future FinTech Group	1.00	Sell	N/A	N/A
INKT MiNK Therapeutics	2.00	Hold	$35.00	194.12% Upside
KROS Keros Therapeutics	2.33	Hold	$20.50	81.26% Upside

Current Analyst Ratings Breakdown

Latest INKT, FTFT, KROS, and ABOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/12/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/14/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/6/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	FTFT Future FinTech Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.16 per share	N/A
FTFT Future FinTech Group	$3.83M	5.12	N/A	N/A	$139.32 per share	0.02
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($3.03) per share	N/A
KROS Keros Therapeutics	$244.06M	0.92	$4.58 per share	2.47	$15.51 per share	0.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.63	N/A	N/A	N/A	N/A	-136.27%	-81.64%	11/11/2026 (Estimated)
FTFT Future FinTech Group	-$4.62M	-$30.16	N/A	N/A	N/A	-157.53%	-12.22%	-10.08%	N/A
INKT MiNK Therapeutics	-$12.49M	-$2.40	N/A	N/A	N/A	N/A	N/A	-92.37%	11/12/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)

Latest INKT, FTFT, KROS, and ABOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	FTFT Future FinTech Group	N/A	-$5.04	N/A	-$1.26	N/A	$0.33 million
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
8/11/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FTFT Future FinTech Group	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.21	2.47	2.47
FTFT Future FinTech Group	N/A	6.71	6.71
INKT MiNK Therapeutics	N/A	1.23	1.23
KROS Keros Therapeutics	N/A	21.96	21.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
FTFT Future FinTech Group	0.19%
INKT MiNK Therapeutics	2.87%
KROS Keros Therapeutics	71.56%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
FTFT Future FinTech Group	1.50%
INKT MiNK Therapeutics	20.40%
KROS Keros Therapeutics	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	72.32 million	64.94 million	Optionable
FTFT Future FinTech Group	70	9.38 million	9.23 million	No Data
INKT MiNK Therapeutics	30	5.10 million	4.06 million	No Data
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable

INKT, FTFT, KROS, and ABOS Headlines

Recent News About These Companies

Share Buyback Program Approved by Keros Therapeutics (NASDAQ:KROS) Board of Directors

2 hours ago | marketbeat.com

Keros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up

September 9 at 7:35 AM | rttnews.com

Keros Therapeutics Approves $5 Million Share Buyback

September 8 at 8:20 PM | marketscreener.comM

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

September 8 at 4:01 PM | globenewswire.com

Wall Street Zen Downgrades Keros Therapeutics (NASDAQ:KROS) to Strong Sell

September 5, 2026 | americanbankingnews.com

Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell"

September 5, 2026 | marketbeat.com

Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS

September 4, 2026 | marketbeat.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts

September 4, 2026 | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts

September 4, 2026 | marketbeat.com

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

September 2, 2026 | zacks.com

Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS

September 2, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS

September 2, 2026 | marketbeat.com

127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd.

August 30, 2026 | marketbeat.com

Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS

August 29, 2026 | marketbeat.com

Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research

August 29, 2026 | marketbeat.com

ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS

August 26, 2026 | marketbeat.com

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

August 24, 2026 | zacks.com

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

August 24, 2026 | zacks.com

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

August 24, 2026 | finance.yahoo.com

Keros Therapeutics (NASDAQ:KROS) Pipeline Progress Gains Focus

August 24, 2026 | kalkinemedia.comK

Keros Therapeutics (NASDAQ:KROS) Raised to Sell at Wall Street Zen

August 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, KROS, and ABOS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.85 -0.31 (-9.81%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$2.82 -0.04 (-1.23%)

As of 09/9/2026 07:30 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Future FinTech Group NASDAQ:FTFT

$2.09 +0.78 (+59.54%)

As of 09/9/2026 04:00 PM Eastern

Future FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People's Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business. It also engages in the trading of coal, aluminum ingots, sand, and steel; and E-commerce, digital wallet safety management, blockchain code auditing and operations, cryptocurrency mining, metaverse and big data maintenance services. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in New York, New York.

MiNK Therapeutics NASDAQ:INKT

$11.90 +0.45 (+3.93%)

Closing price 09/9/2026 03:52 PM Eastern

Extended Trading

$11.92 +0.01 (+0.13%)

As of 09/9/2026 07:30 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Keros Therapeutics NASDAQ:KROS

$11.31 +0.14 (+1.25%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$11.30 -0.01 (-0.04%)

As of 09/9/2026 07:30 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INKT, FTFT, KROS, and ABOS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INKT, FTFT, KROS, and ABOS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INKT, FTFT, KROS, and ABOS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, KROS, and ABOS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Future FinTech Group NASDAQ:FTFT

MiNK Therapeutics NASDAQ:INKT

Keros Therapeutics NASDAQ:KROS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INKT, FTFT, KROS, and ABOS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INKT, FTFT, KROS, and ABOS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INKT, FTFT, KROS, and ABOS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT, FTFT, KROS, and ABOS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Future FinTech Group NASDAQ:FTFT

MiNK Therapeutics NASDAQ:INKT

Keros Therapeutics NASDAQ:KROS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools